Form 4: Tectonic Therapeutic Director McGuire Reports Share Acquisitions Following Merger with AVROBIO

Director Terrance McGuire reports acquisition of common stock and stock options in Tectonic Therapeutic following the merger with AVROBIO, reflecting adjustments from the merger agreement.

Summary

• Terrance McGuire, a director of Tectonic Therapeutic, reported changes in beneficial ownership following the merger between AVROBIO and Tectonic Therapeutic.
• The merger, effective June 20, 2024, involved AVROBIO acquiring Tectonic through a merger subsidiary.
• As a result of the merger, McGuire received 1,073,062 shares of common stock, 20,262 shares of common stock, and 64,652 shares of common stock in exchange for shares of Tectonic common stock.
• These shares are held indirectly through Polaris Partners IX, L.P., Polaris Founders Capital I, LP, and Polaris Founders Capital II, LP.
• McGuire also acquired 11,760 stock options with an exercise price of $16.80, vesting in installments starting June 20, 2025, and expiring on June 19, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate action (merger) and subsequent insider transactions. The sentiment is neutral to slightly positive as it indicates the completion of a strategic move.

Positives

• The acquisition of shares and options indicates continued involvement and potential alignment of interests between the director and the company post-merger.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Mergers and acquisitions are common in the biotech industry as companies seek to expand their pipelines, technologies, or market presence. This Form 4 filing reflects the completion of a merger and the resulting changes in ownership for a key insider.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biotech industry to incentivize performance and align interests with shareholders.
• The vesting schedule of the options (1/3rd after one year, then monthly over the next 24 months) is typical for such grants.
• The conversion ratio of 0.534419990 shares of the Issuer's common stock for each share of Tectonic common stock is specific to the terms negotiated in the merger agreement.

Stakeholder Impact

• Shareholders of both AVROBIO and Tectonic are impacted by the merger, with Tectonic shareholders receiving shares of the combined entity.
• Employees of both companies may experience changes as the organizations integrate.

Key Dates